^
    21h
    Patient Journey Mapping in Oral Cancer Patients Following Free Tissue Transfer: A Retrospective Qualitative Study (ChiCTR2600118655)
    P=N/A, N=20, Shanghai Ninth People’s Hospital affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People’s Hospital affiliated to Sh
    New trial
    21h
    Application of Electrical Stimulation Combined with Exercise Therapy in the Rehabilitation of Dysphagia After Flap Reconstruction for Tongue Cancer (ChiCTR2600118589)
    P=N/A, N=24, Beijing Stomatological Hospital , Capital Medical University; Beijing Stomatological Hospital , Capital Medical University
    New trial
    21h
    Evaluation of Maxillofacial Bone Invasion in Oral and Maxillofacial Squamous Cell Carcinoma Using Philips MR Fracture Sequence (ChiCTR2600118584)
    P=N/A, N=42, Sun Yat-sen Memorial Hospital; Sun Yat-sen Memorial Hospital
    New trial
    21h
    Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    PD-L1 expression • EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    23h
    Study on the consistency of clinical efficacy of PTC in vitro drug sensitivity technology for combined immunotherapy for oral cancer (ChiCTR2500099064)
    P=N/A, N=60, Recruiting, Peking University School and Hospital of Stomatology; Peking University School and Hospital of Stomatology | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    The Application of Goal-Directed Fluid Therapy Under the Guidance of SVV Combined with SVRI in Radical Surgery for Oral Cancer (ChiCTR2600118193)
    P=N/A, N=80, The Second Xiangya Hospital of Central South University; The Second Xiangya Hospital of Central South University
    New trial
    |
    nitroglycerin
    1d
    Advances in the molecular mechanisms and clinical applications of LEMD1 in tumor development and progression (Review). (PubMed, Mol Clin Oncol)
    The present review summarized the research progress of LEMD1 as a cancer-testis antigen in tumor biology. Furthermore, the present review investigated the molecular structure and biological functions of LEMD1, its expression patterns, clinical relevance in various types of tumor, and highlighted current research challenges and future directions.
    Review • Journal
    |
    HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    2d
    Wortmannin exhibits anticancer activity in oral cancer cell line by targeting PI3K, AKT and mTOR pathway. (PubMed, Avicenna J Phytomed)
    This research has revealed wortmannin's ability to treat oral cancer in clinical settings. To validate in-silico and in-vitro findings, more assays and in-vivo research are needed.
    Preclinical • Journal • PARP Biomarker • IO biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • MAPK1 (Mitogen-activated protein kinase 1) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • BAD (BCL2 Associated Agonist Of Cell Death) • BAK1 (BCL2 Antagonist/Killer 1) • MAPK8 (Mitogen-activated protein kinase 8) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    2d
    Cyclooxygenase-2 (COX-2) as a Potential Prognostic Marker in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. (PubMed, Health Sci Rep)
    In conclusion, the present evidence suggests a role of COX-2 overexpression as a prognostic biomarker and in targeted therapy of OSCC patients. Further studies on the role of COX-2 expression might provide a more profound insight into the mechanism of carcinogenesis in OSCC.
    Retrospective data • Review • Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    2d
    Hemidesmosomal Proteins in Oral Cancer Progression: An Immunohistochemical Study of Human and Mouse. (PubMed, J Oral Pathol Med)
    Our findings highlight the importance of biologically targeted region-of-interest selection when assessing hemidesmosomal protein expression in OSCC while demonstrating that BMZ-focused digital analysis provides a more informative approach for exploratory evaluation of heterogeneous human tissues alongside progression-associated patterns observed in a murine model.
    Preclinical • Journal
    |
    DST (Dystonin) • CD151 (CD151 Molecule)
    2d
    Prognostic Significance of CD105-Assessed Angiogenesis in Relation to Survival and Clinicopathological Features of Oral Squamous Cell Carcinoma. (PubMed, J Oral Pathol Med)
    An elevated MVD by CD105 expression is strongly correlated with aggressive HSPL features, stage, nodal metastasis, and poor prognosis in OSCC. In addition to prognostic information, CD105 has the potential to be a target for anti-angiogenic strategies in OSCC indicating its potential use in clinical risk stratification and planning.
    Journal
    |
    ENG (Endoglin) • MVD (Mevalonate Diphosphate Decarboxylase)
    2d
    Pre-operative Serum Hepatocyte Growth Factor and Inflammatory Prognostic Score as Prognostic Markers in Oral Squamous Cell Carcinoma. (PubMed, J Vis Exp)
    Preoperative HGF and IBPS are abnormal in OSCC patients and are associated with postoperative pathological outcomes after 20-month follow-up. These observations may support further investigations into preoperative risk stratification and clinical monitoring for patients with OSCC.
    Retrospective data • Journal
    |
    HGF (Hepatocyte growth factor)